Asher Bio
asherbio.comLighting up only the immune cells that matter
Health & Wellnessbiotechimmunotherapyclinical-stageoncologyil-2drug-developmenttherapeutics
About
Asher Biotherapeutics is a clinical-stage biotech company developing cis-targeted immunotherapies that selectively activate specific immune cell types to improve efficacy and reduce side effects. Their lead molecule, etakafusp alfa (AB248), is a cis-targeted IL-2 designed to specifically activate CD8+ effector T cells and is currently in Phase 1a/1b clinical trials. The company focuses on overcoming the limitations of conventional immunotherapies that act indiscriminately across multiple cell types.
Problem
Conventional immunotherapies indiscriminately activate multiple immune cell types, leading to suboptimal efficacy and harmful side effects.
For
oncology patients and clinical researchers
How it works
Cis-targeted immunotherapies engage both an immunomodulatory receptor and a cell-type-specific target on the same immune cell, activating only the desired immune cell population.
Business model
unknown
Status
launched
Company
Asher Biotherapeutics